sellWeak cluster of 410b5-1 plan
Darlene Noci sold $412k of NUVL
Chief Development Officer at Nuvalent, Inc.. 4,000 shares at an average of $102.92, traded Oct 30, 2025, filed Oct 31, 2025.
Warning score
11Value
$412k
4,000 shares
Holdings after
48,034
-8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +16Trade size$412k at market
- 0Share of holdings soldSold 7.7% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-260859, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 30, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,000 | $27.85 | $111k | 52,034 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -57 | $98.91 | $5,638 | 51,977 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -350 | $100.69 | $35k | 51,627 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,170 | $102.07 | $119k | 50,457 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,091 | $103.09 | $112k | 49,366 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,114 | $104.21 | $116k | 48,252 | Oct 31, 2025 |
| Oct 30, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -218 | $104.58 | $23k | 48,034 | Oct 31, 2025 |
| Oct 30, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 122,329 | Oct 31, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 23Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $721k 7,417 shares | -8% | |
| 44Moderate | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $782k 7,084 shares | -11% | |
| 12Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $434k 4,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Matthew Shair director | $820k 7,500 shares | -1% | |
| 55Moderate | Nuvalent, Inc. | James E Flynn director, owner, other | $71M 742,574 shares | -9% | |
| 37Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.1M 20,729 shares | -25% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.6M 24,200 shares | -33% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.2M 21,800 shares | -31% | |
| 35Weak | Nuvalent, Inc. | Matthew Shair director | $6.0M 60,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.